Enhancement of transgene expression by cotransfection of oriP plasmid with EBNA-1 expression vector

Human Gene Therapy

Volumn 11, Issue 3, 2000, Pages 471-479

  Kaneda, Yasufumi ^a,b   Saeki, Yoshinaga ^a   Nakabayashi, Mari ^a   Zhou, Wen Zhong ^a   Kaneda, Mari Wataya ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; LIPOSOME; LUCIFERASE; VIRUS DNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PLASMID; TRANSGENE;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CELL LINE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; HUMANS; LIVER; LUCIFERASES; MICE; MICE, INBRED C57BL; PLASMIDS; REPLICATION ORIGIN; RESPIROVIRUS; TRANSGENES;

ANIMALIA; CUCUMBER MOSAIC VIRUS; DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 0034628550     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015932     Document Type: Article

References (45)

1. AMBINDER, R.F., SHAH, W.A., RAWLINS, D.R., HAYWARD, G.S., and HAYWARD, S.D. (1990). Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus. J. Virol. 64, 2369-2379.
2. CALOS, M.P. (1996). The potential of extrachromosomal replicating vectors for gene therapy. Trends Genet. 12, 463-466.
3. CHEN, W.-Y., BAILEY, E.C., MCCUNE, S.L., DONG, J.-Y., and TOWNES, T.M. (1997). Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc. Natl. Acad. Sci. U.S.A. 94, 5798-5803.
4. COHEN, J.I., WANG, F., MANNICK, J., and KIEFF, E. (1989). Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. U.S.A. 86, 9558-9562.
5. DION, L.D., GOLDSMITH, K.T., TANG, D.PC., ENGLER, J.A., YOSHIDA, M., and GARVER, R.I., JR. (1997). Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology 231, 201-209.
6. FRAPPIER, L., and O'DONNELL, M. (1991). Overproduction, purification and characterization of EBNA-1, the origin binding protein of Epstein-Barr virus. J. Biol. Chem. 266, 7819-7826.
7. GOSSEN, M., FREUNDLIEB, S., BENDER, G., MULLER, G., HILLEN, W., and BUJARD, H. (1995). Transcriptional activation by tetracyclins in mammalian cells. Science 268, 1766-1769.
8. GREBER, U.F., SUOMALAINEN, M., STIDWILL, R.P., BOUCKE, K., EBERSOLD, M.W., and HELENIUS, A. (1997). The role of the nuclear pore complex in adenovirus DNA entry. EMBO J. 16, 5998-6007.
9. HAMMERSCHMIDT, W., and SUGDEN, B. (1989). Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature (London) 340, 393-397.
10. HODGSON, C.P., XU, G., SOLAIMAN, F., and ZINK, M.A. (1997). Biosynthetic retrovectoring systems for gene therapy. J. Mol. Med. 75, 249-258.
11. JONES, C.H., HAYWARD, S.D., and RAWLINS, D.R. (1989). Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites. J. Virol. 63, 101-110.
12. JOX, A., ROHEN, C., BELGE, G., BARTNITZKE, S., PAWLITA, M., DIEHL, V., BULLERDIEK, J., and WOLF, J. (1997). Integration of Epstein-Barr virus in Burkitt's lymphoma cells leads to a region of enhanced chromosome instability. Ann. Oncol. 8(Suppl. 2), 131-135.
13. KANEDA Y., IWAI, K., and UCHIDA, T. (1989a). Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 243, 375-378.
14. KANEDA, Y., IWAI, K., and UCHIDA, T. (1989b). Introduction and expression of the human insulin gene in adult rat liver. J. Biol. Chem. 264, 12126-12129.
15. KANN, M., BISCHOF, A., and GERLICH, W.H. (1997). In vitro model for the nuclear transport of the hepadnavirus genome. J. Virol. 71, 1310-1316.
16. KAYE, K.M., IZUMI, K.M., and KIEFF, E. (1993). Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. U.S.A. 90, 9150-9154.
17. KELLEHER, Z.T., FU, H., ELIZABETH, L., WENDELBURG, B., GULINO, S., and VOS, J.-M. (1998). Epstein-Barr-based episomal chromosomes shuttle 100 kb of self-replicating circular human DNA in mouse cells. Nature Biotechnol. 16, 762-768.
18. KINOSHTTA, K., KANEDA Y., SATO, M., WATAYA-KANEDA, M., SAEKI, Y., HOFFMANN, A., and KANEDA, Y. (1998). LBP-p40 binds DNA tightly through associations with histones H2A, H2B, and H4. Biochem. Biophys. Res. Commun. 253, 277-282.
19. KISTNER, A., GOSSEN, M., ZIMMERMANN, F., JERECIC, J., ULLMER, C., LUBBERT, H., and BUJARD, H. (1996). Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 93, 10993-10998.
20. LANGLE-ROUAULT, F., PATZEL, V., BENAVENTE, A., TAILEZ, M., SILVESTRE, N., BOMPARD, A., SCZAKIEL, G., JACOBS, E., and RITTNER, K. (1998). Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: Implications of the nuclear import of plasmids. J. Virol. 72, 6181-6185.
21. LEDLEY, F.D. (1995). Nonviral gene therapy; the promise of genes as pharmaceutical products. Hum. Gene Ther. 6, 1129-1144.
22. LESTOU, V.S., DE-BRAEKELEER, M., STREHL, S., OTT, G., GADNER, H., and AMBROS, P.F. (1993). Non-random integration of Epstein-Barr virus in lymphoblastoid cell lines. Genes Chromosomes Cancer 8, 38-48.
23. LINDAHL, T., ADAMS, A., BJURSELL, G., BOMKAMM, G.W., KASCHKA-DIERICH, C., and JEHN, U. (1976). Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J. Mol. Biol. 102, 511-530.
24. LUPTON, S., and LEVINE, A.J. (1985). Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus derived plasmids in human cells. Mol. Cell. Biol. 5, 2533-2542.
25. MARSHALL, E. (1995). Gene therapy's growing pains. Science 269, 1052-1055.
26. MURAMATSU, M., HAYASHI, Y., ONISHI, T., SAKAI, M., TAKAI, K., and KASHIYAMA, T. (1974). Rapid isolation of nucleoli from detergent purified nuclei of various tumor and tissue culture cells. Exp. Cell Res. 88, 345-351.
27. NALDINI, L., BLOMER, U., GALLAY, P., ORY, D., MULLIGAN, R., GAGE, F.H., VERMA, I.M., and TORONO, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentivirus vector. Science 272, 263-267.
28. RAWLINS, D.R., MILMAN, G., HAYWARD, S.D., and HAYWARD, G.S. (1985). Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in plasmid maintenance. Cell 42, 859-868.
29. REISMAN, D., and SUGDEN, B. (1986). Trans-activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr virus nuclear antigen 1. Mol. Cell. Biol. 6, 3838-3846.
30. REISMAN, D., YATES, J., and SUGDEN, B. (1985). A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol. Cell. Biol. 5, 1822-1832.
31. ROBERTSON, E.S., OOKA, T., and KIEFF, E.D. (1996). Epstein-Barr virus vectors for gene delivery to B lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 93, 11334-11340.
32. SAEKI, Y., MATSUMOTO, N., NAKANO, Y., MORI, M., AWAI, K., and KANEDA, Y. (1997). Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): Reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum. Gene Ther. 8, 1965-1972.
33. SAEKI, Y., WATAYA-KANEDA, M., TANAKA K., and KANEDA, Y. (1998). Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ-liposomes. Gene Ther. 5, 1031-1037.
34. SEBESTYEN, M.G., LUDTKE, J.J., BASSIK, M.C., ZHANG, G., BUDKER, V., LUKHTANOV, E.A., HAGSTROM, J.E., and WOLFF, J.A. (1998). DNA vector chemistry: The covalent attachment of signal peptides to plasmid DNA. Nature Biotechnol. 16, 80-85.
35. SUGDEN, B., and WARREN, N. (1989). A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J. Virol. 63, 2644-2649.
36. TOMKINSON, B., ROBERTSON, E., and KIEFF, E. (1993). Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67, 2014-2025.
37. TRIVEDI, P., HU, L.F., CHEN, B., CHRISTENSSON, B., MASUCCI, M.G., KLEIN, G., and WINBERG, G. (1994). Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur. J. Cancer 30A, 84-88.
38. VIDAL, M., WRIGHTON, C., ECCLES, S., BURKE, J., and GROSVELD, F. (1990). Differences in human cell lines to support stable replication of Epstein-Barr virus-based vectors. Biochim. Biophys. Acta 1048, 171-177.
39. WILSON, J.B., and LEVINE, A.J. (1992). The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. Curr. Top. Microbiol. Immunol. 182, 375-384.
40. WILSON, J.B., BELL, J.L., and LEVINE, A.L. (1996). Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 15, 3117-3126.
41. WYSOKENSKI, D.A., and YATES, J.L. (1989). Multiple EBNA-1 binding sites are required to form an EBNA-1-dependent enhancer and to activate a minimal replication origin within oriP of Epstein-Barr virus. J. Virol. 63, 2657-2666.
42. YATES, J.L., WARREN, N., and SUGDEN, B. (1985). Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (London) 313, 812-815.
43. YOSHIDA, M., HORINOUCHI, S., and BEPPU, T. (1995). Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17, 423-430.
44. ZABNER, J., FASBENDER, A.J., MONINGER, T., POELLINGER, K.A., and WELSH, M.J. (1995). Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biol. Chem. 270, 18997-19007.
45. ZHOU, W.-Z., KANEDA, Y., HUANG, S.K.S., MORISHITA, R., and HOON, D.S.B. (1999). Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Ther. 6, 1768-1773.